Study | Stage | Ph | Pts. | Design | Primary end point | NCT number | Primary completion |
---|---|---|---|---|---|---|---|
First-line | |||||||
 KEYNOTE-604 | ED | III | 453 | Pembro+EP v Placebo+EP | PFS, OS | NCT03066778 | December 2019 |
 REACTION | ED | II | 118 | Pembro+EP v EP | 6-month PFS | NCT02580994 | August 2020 |
  NA | LD/ED | I | 80 | Pembro+EP ± RT | MTD | NCT02402920 | July 31, 2023 |
  NA | LD | II / III | 506 | Atezo+EP+RT v EP+RT | PFS, OS | NCT03811002 | May 2024 |
 CASPIAN | ED | III | 988 | Durva±Treme+EP v EP | PFS, OS | NCT030s43872 | September 2019 |
 CLOVER | LDb | I | 300 | Durva±Treme+EP | DLT; AE | NCT03509012 | April 2022 |
  PAVE | ED | II | 55 | Avelumab+EP | 1- year PFS | NCT03568097 | November 2020 |
Second-line and beyond | |||||||
 BLOLUMA | LD/EDa | II | 106 | Nivo+Ipi | ORR | NCT03083691 | March 2019 |
 MCC-19163 | LD/ED | II | 41 | Nivo+Ipi+Ad.p53-DC vaccine | DCR | NCT03406715 | April 2020 |
 CA209-9YT | ED | II | 40 | Nivo+Ipi | Teff/Treg | NCT03670056 | September 2020 |
  NA | ED | II | 29 | Nivo+Gemcitabine | ORR | NCT03662074 | September 2020 |
  AFT-17 | LD/ED | II | 98 | Pembro v Topotecan | PFS | NCT02963090 | May 2019 |
 KEYNOTE PN758 | ED | I/ II | 84 | Pembro+Pegzilarginase | AE, ORR | NCT03371979 | December 2020 |
  NA | LD/ED | II | 80 | Pembro+EP±RT | PD-L1 | NCT02934503 | October 2019 |
 ML39728 | LD/ED | II | 35 | Atezo | ORR | NCT03262454 | December 2019 |
 Winship3112-15 | LD/ED | II | 28 | Durva±Treme+RT v RT | PFS, ORR | NCT02701400 | January 2020 |
 PASSION | ED | II | 135 | SHR-1210+Apatinib | AE, ORR | NCT03417895 | March 2019 |
Maintenance | |||||||
 STIMULI | LD | II | 260 | Nivo+Ipi v Obsesrvation | PFS, OS | NCT02046733 | October 2019 |
 CA209-840 | ED | I/ II | 21 | Nivo+Ipi+RT | PFS | NCT03043599 | April 2021 |
 ACHILES | LD | II | 212 | Atezo v Observation | 2-year OS | NCT03540420 | December 2023 |
  NA | LD | II | 51 | Durva+EP+RT | PFS | NCT03585998 | June 2021 |
 ADRIATIC | LD | III | 600 | Durva±Treme v Placebo | PFS, OS | NCT03703297 | June 2021 |